1,5-氧氮杂环辛烷 | 107261-17-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,5-氧氮杂环辛烷
• 中文别名: 苯甲酸,4,4'-[1,3-丙二基二(氧代)]二-,均聚物
• 英文名称: hexahydro-2H-1,5-oxaazacyclooctane
• 英文别名: 1,5-oxaazacyclooctane；1,5-oxaazacyclooctan；1,5-oxazacyclooctane；1,5-oxazocane；1,5-oxazocan；Perhydro-1,5-oxazocine
• CAS: 107261-17-6
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: BMTZFAWRALJMOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,5-氧氮杂环辛烷 在 potassium fluoride 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 22.0h， 生成 5-[7-chloro-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-1,5-oxazocane
  参考文献：
  名称：

  [EN] BICYCLIC DERIVATIVES AND USE THEREOF
  [FR] DÉRIVÉS BICYCLIQUES ET LEUR UTILISATION

  摘要：

  A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.

  公开号：

  WO2023020523A1
• 作为产物：
  描述：

  tert-butyl 1,5-oxazocane-5-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1,5-氧氮杂环辛烷
  参考文献：
  名称：

  [EN] BICYCLIC DERIVATIVES AND USE THEREOF
  [FR] DÉRIVÉS BICYCLIQUES ET LEUR UTILISATION

  摘要：

  A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.

  公开号：

  WO2023020523A1

文献信息

• [EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018183411A1

  公开（公告）日：2018-10-04

  Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  公式（I）的化合物被披露为DCNl的抑制剂，以及含有这些化合物的组合物。还披露了在治疗疾病和病况中使用DCNl抑制剂的方法，其中DCNl的抑制提供益处，如氧化应激相关的疾病和病况、神经退行性疾病和病况、代谢紊乱以及肌肉神经退化。
• Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20180289677A1

  公开（公告）日：2018-10-11

  Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  揭示了DCN1的小分子共价抑制剂和含有这些抑制剂的组合物。还揭示了在治疗疾病和状况中使用DCN1共价抑制剂的方法，其中DCN1的抑制提供益处，如氧化应激相关的疾病和状况、神经退行性疾病和状况、代谢紊乱以及肌肉神经退化。
• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2014151958A1

  公开（公告）日：2014-09-25

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了一些能够调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，所述化合物能够抑制β-内酰胺酶。在特定实施例中，所述化合物在治疗细菌感染方面具有用处。
• HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150259343A1

  公开（公告）日：2015-09-17

  The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor, and processes for preparing such compounds and compositions.

  本发明涉及携带环状取代基的三环六氢二氮杂喹啉类化合物，以及生产它们的方法，含有这类化合物的药物组合物，它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的药物，用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的方法，以及制备这类化合物和组合物的方法。
• 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use
  申请人：Askew C. Benny

  公开号：US20060025400A1

  公开（公告）日：2006-02-02

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和疾病，如炎症介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，药物组合物以及用于预防和治疗涉及疼痛、炎症等疾病和其他不适或情况的方法。该发明还涉及制备此类化合物的方法，以及在此类过程中有用的中间体。